23 results on '"Furstenau, Moritz"'
Number of results to display per page
Search Results
2. Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study
- Author
-
Visentin, Andrea, primary, Scarfò, Lydia, additional, Chatzikonstantinou, Thomas, additional, Kapetanakis, Anargyros, additional, Demosthenous, Christos, additional, Karakatsoulis, Georgios, additional, Andres, Martin, additional, Antic, Darko, additional, Allsup, David, additional, Baile, Mónica, additional, Bron, Dominique, additional, Capasso, Antonella, additional, Catherwood, Mark, additional, Collado, Rosa, additional, Cordoba, Raul, additional, Cuéllar-García, Carolina, additional, Delgado, Julio, additional, Dimou, Maria, additional, Doubek, Michael, additional, De Paoli, Lorenzo, additional, De Paolis, Maria Rosaria, additional, Del Poeta, Giovanni, additional, Efstathopoulou, Maria, additional, Shimaa, El-Ashwah, additional, Enrico, Alicia, additional, Farina, Lucia, additional, Ferrari, Angela, additional, Foglietta, Myriam, additional, Furstenau, Moritz, additional, Garcia-Marco, Jose A., additional, Gentile, Massimo, additional, Gimeno, Eva, additional, Maria, Gomes da Silva, additional, Gutwein, Odit, additional, Hakobyan, Yervand, additional, Herishanu, Yair, additional, Hernandez, jose Angel, additional, Herold, Tobias, additional, Iyengar, Sunil, additional, Itchaki, Gilad, additional, Jaksic, Ozren, additional, Janssens, Ann, additional, Kalashnikova, Olga, additional, Kalicinska, Elzbieta, additional, Kater, Arnon P., additional, Kersting, Sabina, additional, Labrador, Jorge, additional, Lad, Deepesh, additional, Laurenti, Luca, additional, Levin, Mark-David, additional, Lista, Enrico, additional, Malerba, Lara, additional, Marasca, Roberto, additional, Marchetti, Monia, additional, Marquet Palomanes, Juan, additional, Mattsson, Mattias, additional, Mauro, Francesca Romana, additional, Mayor-Bastida, Carlota, additional, Morawska, Marta, additional, Motta, Marina, additional, Munir, Talha, additional, Murru, Roberta, additional, Milosevic, Ivana, additional, Miras Calvo, Fatima, additional, Niemann, Carsten Utoft, additional, Olivieri, Jacopo, additional, Orsucci, Lorella, additional, Papaioannou, Maria, additional, Pavlovsky, Miguel Arturo, additional, Piskunova, Inga S., additional, Pocali, Barbara, additional, Popov, Viola Maria, additional, Quaglia, Francesca Maria, additional, Quaresmini, Giulia, additional, Raa, Doreen te, additional, Reda, Gianluigi, additional, Rigolin, Gian Matteo, additional, Ruchlemer, Rosa, additional, Shrestha, Amit, additional, Šimkovič, Martin, additional, Špaček, Martin, additional, Sportoletti, Paolo, additional, Stanca Ciocan, Oana, additional, Tadmor, Tamar, additional, Vandenberghe, Elisabeth, additional, Varettoni, Marzia, additional, Vitale, Candida, additional, Van Der Spek, Ellen, additional, Van Gelder, Michel, additional, Wasik-Szczepanek, Ewa, additional, Yáñez, Lucrecia, additional, Yassin, Mohamed A, additional, Coscia, Marta, additional, Eichhorst, Barbara, additional, Rambaldi, Alessandro, additional, Stavroyianni, Niki, additional, Trentin, Livio, additional, Stamatopoulos, Kostas, additional, and Ghia, Paolo, additional
- Published
- 2022
- Full Text
- View/download PDF
3. High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations
- Author
-
Furstenau, Moritz, primary, Thus, Yvonne, additional, Robrecht, Sandra, additional, Mellink, Clemens, additional, Van Der Kevie-Kersemaekers, Anne-Marie, additional, Dubois, Julie M.N., additional, Von Tresckow, Julia, additional, Patz, Michaela, additional, Gregor, Michael, additional, Thornton, Patrick, additional, Staber, Philipp B., additional, Tadmor, Tamar, additional, Levin, Mark-David, additional, Da Cunha-Bang, Caspar, additional, Schneider, Christof, additional, Poulsen, Christian Bjørn, additional, Illmer, Thomas, additional, Schöttker, Björn, additional, Janssens, Ann, additional, Christiansen, Ilse, additional, Baumann, Michael, additional, Noesslinger, Thomas, additional, Regelink, Josien, additional, Dompeling, Ellen C, additional, Lindström, Vesa, additional, Juliusson, Gunnar, additional, Widmer, Anouk, additional, Goede, Jeroen Simon, additional, Goldschmidt, Neta, additional, Simon, Florian, additional, De Silva, Nisha, additional, Fink, Anna-Maria, additional, Fischer, Kirsten, additional, Wendtner, Clemens-Martin, additional, Ritgen, Matthias, additional, Brüggemann, Monika, additional, Tausch, Eugen, additional, Stilgenbauer, Stephan, additional, Eldering, Eric, additional, Niemann, Carsten Utoft, additional, Hallek, Michael, additional, Eichhorst, Barbara, additional, Kreuzer, Karl-Anton, additional, and Kater, Arnon P., additional
- Published
- 2022
- Full Text
- View/download PDF
4. Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial
- Author
-
Tausch, Eugen, primary, Schneider, Christof, additional, Furstenau, Moritz, additional, Robrecht, Sandra, additional, Yosifov, Deyan Yordanov, additional, Mertens, Daniel, additional, Gregor, Michael, additional, Thornton, Patrick, additional, Staber, Philipp B., additional, Tadmor, Tamar, additional, Levin, Mark-David, additional, da Cunha-Bang, Caspar, additional, Poulsen, Christian Bjørn, additional, Illmer, Thomas, additional, Schöttker, Björn, additional, Janssens, Ann, additional, Christiansen, Ilse, additional, Noesslinger, Thomas, additional, Baumann, Michael, additional, Wendtner, Clemens-Martin, additional, Eldering, Eric, additional, Kreuzer, Karl-Anton, additional, Ritgen, Matthias, additional, Fink, Anna-Maria, additional, Fischer, Kirsten, additional, Kater, Arnon P., additional, Niemann, Carsten Utoft, additional, Hallek, Michael, additional, Eichhorst, Barbara, additional, and Stilgenbauer, Stephan, additional
- Published
- 2022
- Full Text
- View/download PDF
5. Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation
- Author
-
Huber, Henriette, primary, Tausch, Eugen, additional, Schneider, Christof, additional, Edenhofer, Simone, additional, Von Tresckow, Julia, additional, Robrecht, Sandra, additional, Giza, Adam, additional, Zhang, Can, additional, Furstenau, Moritz, additional, Dreger, Peter, additional, Ritgen, Matthias, additional, Illmer, Thomas, additional, Illert, Anna Lena, additional, Dürig, Jan, additional, Böttcher, Sebastian, additional, Niemann, Carsten Utoft, additional, Kneba, Michael, additional, Fink, Anna-Maria, additional, Fischer, Kirsten, additional, Döhner, Hartmut, additional, Hallek, Michael, additional, Eichhorst, Barbara, additional, and Stilgenbauer, Stephan, additional
- Published
- 2022
- Full Text
- View/download PDF
6. Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax
- Author
-
Furstenau, Moritz, Weiss, Jonathan, Giza, Adam, Franzen, Fabian, Robrecht, Sandra, Fink, Anna-Maria, Fischer, Kirsten, Schneider, Christof, Tausch, Eugen, Stilgenbauer, Stephan, Ritgen, Matthias, Schilhabel, Anke, Brueggemann, Monika, Eichhorst, Barbara, Hallek, Michael, Cramer, Paula, Furstenau, Moritz, Weiss, Jonathan, Giza, Adam, Franzen, Fabian, Robrecht, Sandra, Fink, Anna-Maria, Fischer, Kirsten, Schneider, Christof, Tausch, Eugen, Stilgenbauer, Stephan, Ritgen, Matthias, Schilhabel, Anke, Brueggemann, Monika, Eichhorst, Barbara, Hallek, Michael, and Cramer, Paula
- Abstract
Purpose: With the advent of highly efficacious time-limited combination treatments of targeted agents in chronic lympho-cytic leukemia (CLL), minimal residual disease (MRD) assess-ment has gained importance as a measure for therapeutic success and as a surrogate for progression-free survival. The currently most widely used method is multicolor flow cytometry, which detects circulating CLL cells in the peripheral blood. However, it seems to be less sensitive for the detection of MRD in the lymph node compartment. Patients and Methods: To evaluate whether a cell-free approach can overcome this limitation, we performed serial assess-ments of circulating tumor DNA (ctDNA) in patients with CLL treated with obinutuzumab, acalabrutinib, and veneto-clax in the phase II CLL2-BAAG trial. Patient-specific vari-ability, diversity, joining (VDJ) rearrangements as well as somatic driver mutations were tracked before, during and after treatment by digital droplet PCR in blood plasma. Furthermore, these were systematically compared to matched flow cytometry data.Results: In the 381 sample pairs, ctDNA and flow cytometry yielded highly concordant results. However, clone-specific ctDNA was detected in 44 of 152 samples (29%) that were assessed as undetectable MRD (uMRD) by flow cytometry (defined as less than one CLL cell in 10,000 normal leukocytes). 29 ctDNA-negative samples showed detectable MRD >10-4 by flow cytometry. Also, somatic driver mutations were detected with a similar sensitivity compared with patient-specific VDJ rearrangements in plasma. In patients with predominantly nodal residual disease, ctDNA com-pared favorably with 4-color flow cytometry and seemed to more accurately reflect the entire disease burden across compartments. Conclusions: On the basis of these findings, ctDNA-based MRD assessment appears to be a promising method to comple-ment cell-based MRD approaches like flow cytometry that focus on circulating CLL cells in the peripheral blood.
- Published
- 2022
7. Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study
- Author
-
Visentin, Andrea, Scarfo, Lydia, Chatzikonstantinou, Thomas, Kapetanakis, Anargyros, Demosthenous, Christos, Karakatsoulis, Georgios, Andres, Martin, Antic, Darko, Allsup, David, Baile, Monica, Bron, Dominique, Capasso, Antonella, Catherwood, Mark, Collado, Rosa, Cordoba, Raul, Cuellar-Garcia, Carolina, Delgado, Julio, Dimou, Maria, Doubek, Michael, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Efstathopoulou, Maria, Shimaa, El-Ashwah, Enrico, Alicia, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Furstenau, Moritz, Garcia-Marco, Jose A., Gentile, Massimo, Gimeno, Eva, Maria, Gomes da Silva, Gutwein, Odit, Hakobyan, Yervand, Herishanu, Yair, Hernandez, Jose Angel, Herold, Tobias, Iyengar, Sunil, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Olga, Kalicinska, Elzbieta, Kater, Arnon P., Kersting, Sabina, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Palomanes, Juan Marquet, Mattsson, Mattias, Mauro, Francesca Romana, Mayor-Bastida, Carlota, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Milosevic, Ivana, Calvo, Fatima Miras, Niemann, Carsten Utoft, Olivieri, Jacopo, Orsucci, Lorella, Papaioannou, Maria, Pavlovsky, Miguel Arturo, Piskunova, Inga S., Pocali, Barbara, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, te Raa, Doreen, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Shrestha, Amit, Simkovic, Martin, Spacek, Martin, Sportoletti, Paolo, Ciocan, Oana Stanca, Tadmor, Tamar, Vandenberghe, Elisabeth, Varettoni, Marzia, Vitale, Candida, Van der Spek, Ellen, Van Gelder, Michel, Wasik-Szczepanek, Ewa, Yanez, Lucrecia, Yassin, Mohamed A., Coscia, Marta, Eichhorst, Barbara, Rambaldi, Alessandro, Stavroyianni, Niki, Trentin, Livio, Stamatopoulos, Kostas, Ghia, Paolo, Visentin, Andrea, Scarfo, Lydia, Chatzikonstantinou, Thomas, Kapetanakis, Anargyros, Demosthenous, Christos, Karakatsoulis, Georgios, Andres, Martin, Antic, Darko, Allsup, David, Baile, Monica, Bron, Dominique, Capasso, Antonella, Catherwood, Mark, Collado, Rosa, Cordoba, Raul, Cuellar-Garcia, Carolina, Delgado, Julio, Dimou, Maria, Doubek, Michael, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Efstathopoulou, Maria, Shimaa, El-Ashwah, Enrico, Alicia, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Furstenau, Moritz, Garcia-Marco, Jose A., Gentile, Massimo, Gimeno, Eva, Maria, Gomes da Silva, Gutwein, Odit, Hakobyan, Yervand, Herishanu, Yair, Hernandez, Jose Angel, Herold, Tobias, Iyengar, Sunil, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Olga, Kalicinska, Elzbieta, Kater, Arnon P., Kersting, Sabina, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Palomanes, Juan Marquet, Mattsson, Mattias, Mauro, Francesca Romana, Mayor-Bastida, Carlota, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Milosevic, Ivana, Calvo, Fatima Miras, Niemann, Carsten Utoft, Olivieri, Jacopo, Orsucci, Lorella, Papaioannou, Maria, Pavlovsky, Miguel Arturo, Piskunova, Inga S., Pocali, Barbara, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, te Raa, Doreen, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Shrestha, Amit, Simkovic, Martin, Spacek, Martin, Sportoletti, Paolo, Ciocan, Oana Stanca, Tadmor, Tamar, Vandenberghe, Elisabeth, Varettoni, Marzia, Vitale, Candida, Van der Spek, Ellen, Van Gelder, Michel, Wasik-Szczepanek, Ewa, Yanez, Lucrecia, Yassin, Mohamed A., Coscia, Marta, Eichhorst, Barbara, Rambaldi, Alessandro, Stavroyianni, Niki, Trentin, Livio, Stamatopoulos, Kostas, and Ghia, Paolo
- Published
- 2022
8. Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial
- Author
-
Tausch, Eugen, Schneider, Christof, Furstenau, Moritz, Robrecht, Sandra, Yosifov, Deyan Yordanov, Mertens, Daniel, Gregor, Michael, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Levin, Mark-David, Da Cunha-Bang, Caspar, Poulsen, Christian Bjorn, Illmer, Thomas, Schoettker, Bjoern, Janssens, Ann, Christiansen, Ilse, Noesslinger, Thomas, Baumann, Michael, Wendtner, Clemens-Martin, Eldering, Eric, Kreuzer, Karl-Anton, Ritgen, Matthias, Fink, Anna-Maria, Fischer, Kirsten, Kater, Arnon P., Niemann, Carsten Utoft, Hallek, Michael, Eichhorst, Barbara, Stilgenbauer, Stephan, Tausch, Eugen, Schneider, Christof, Furstenau, Moritz, Robrecht, Sandra, Yosifov, Deyan Yordanov, Mertens, Daniel, Gregor, Michael, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Levin, Mark-David, Da Cunha-Bang, Caspar, Poulsen, Christian Bjorn, Illmer, Thomas, Schoettker, Bjoern, Janssens, Ann, Christiansen, Ilse, Noesslinger, Thomas, Baumann, Michael, Wendtner, Clemens-Martin, Eldering, Eric, Kreuzer, Karl-Anton, Ritgen, Matthias, Fink, Anna-Maria, Fischer, Kirsten, Kater, Arnon P., Niemann, Carsten Utoft, Hallek, Michael, Eichhorst, Barbara, and Stilgenbauer, Stephan
- Published
- 2022
9. Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/TP53 Mutation
- Author
-
Huber, Henriette, Tausch, Eugen, Schneider, Christof, Edenhofer, Simone, Von Tresckow, Julia, Robrecht, Sandra, Giza, Adam, Zhang, Can, Furstenau, Moritz, Dreger, Peter, Ritgen, Matthias, Illmer, Thomas, Illert, Anna Lena, Duerig, Jan, Boettcher, Sebastian, Niemann, Carsten Utoft, Kneba, Michael, Fink, Anna-Maria, Fischer, Kirsten, Doehner, Hartmut, Hallek, Michael, Eichhorst, Barbara, Stilgenbauer, Stephan, Huber, Henriette, Tausch, Eugen, Schneider, Christof, Edenhofer, Simone, Von Tresckow, Julia, Robrecht, Sandra, Giza, Adam, Zhang, Can, Furstenau, Moritz, Dreger, Peter, Ritgen, Matthias, Illmer, Thomas, Illert, Anna Lena, Duerig, Jan, Boettcher, Sebastian, Niemann, Carsten Utoft, Kneba, Michael, Fink, Anna-Maria, Fischer, Kirsten, Doehner, Hartmut, Hallek, Michael, Eichhorst, Barbara, and Stilgenbauer, Stephan
- Published
- 2022
10. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG) a multicentre, open-label, phase 2 trial
- Author
-
Cramer, Paula, Furstenau, Moritz, Robrecht, Sandra, Giza, Adam, Zhang, Can, Fink, Anna-Maria, Fischer, Kirsten, Langerbeins, Petra, Al-Sawaf, Othman, Tausch, Eugen, Schneider, Christof, Schetelig, Johannes, Dreger, Peter, Bottcher, Sebastian, Kreuzer, Karl-Anton, Schilhabel, Anke, Ritgen, Matthias, Bruggemann, Monika, Kneba, Michael, Stilgenbauer, Stephan, Eichhorst, Barbara, Hallek, Michael, Cramer, Paula, Furstenau, Moritz, Robrecht, Sandra, Giza, Adam, Zhang, Can, Fink, Anna-Maria, Fischer, Kirsten, Langerbeins, Petra, Al-Sawaf, Othman, Tausch, Eugen, Schneider, Christof, Schetelig, Johannes, Dreger, Peter, Bottcher, Sebastian, Kreuzer, Karl-Anton, Schilhabel, Anke, Ritgen, Matthias, Bruggemann, Monika, Kneba, Michael, Stilgenbauer, Stephan, Eichhorst, Barbara, and Hallek, Michael
- Abstract
Background Although BTK inhibitors provide long-term disease-control in patients with chronic lymphocytic leukaemia, they need to be combined with BCL2 inhibitors or antibodies to achieve deep responses with undetectable minimal residual disease (uMRD), which allows for time-limited treatment. This trial aims to evaluate the triple combination of obinutuzumab, acalabrutinib, and venetoclax after an optional debulking with bendamustine. Methods This multicentre, open-label, investigator-initiated, phase 2 study evaluates a sequential treatment consisting of a debulking with two cycles of bendamustine for patients with a higher tumour load (70 mg/m(2) intravenously on days 1 and 2, repeated after 28 days), followed by an induction and a maintenance with obinutuzumab (1000 mg intravenously on days 1-2, 8, and 15 of the first induction cycle, every 4 weeks in induction cycles 2-6 and every 12 weeks in the maintenance phase), acalabrutinib (100 mg orally twice daily continuously from induction cycle 2 day 1 onwards) and venetoclax (starting in induction cycle 3 with 20 mg per day with a weekly dose ramp-up over 5 weeks to the target dose of 400 mg per day). Eligible patients were aged 18 years or older with an ECOG performance score 0-2 and had relapsed or refractory chronic lymphocytic leukaemia requiring treatment according to the 2018 International Workshop on Chronic Lymphocytic Leukemia criteria. The primary endpoint was uMRD (< 10-4) in peripheral blood at the end of induction treatment assessed centrally at the final restaging, 12 weeks after the start of the last induction cycle. As per protocol, all patients with more than two induction cycles were included in the analyses. This study is registered with ClinicalTrials.gov, number NCT03787264, and is ongoing. Findings Between Jan 14, 2019, and June 25, 2020, 45 evaluable patients with relapsed or refractory chronic lymphocytic leukaemia were enrolled; 13 (29%) were female, 32 (71%) were male, 21 (47%) had already
- Published
- 2022
11. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
- Author
-
Chatzikonstantinou, Thomas Kapetanakis, Anargyros Scarfo, Lydia and Karakatsoulis, Georgios Allsup, David Alonso Cabrero, Alejandro Andres, Martin Antic, Darko Baile, Monica and Baliakas, Panagiotis Bron, Dominique Capasso, Antonella and Chatzileontiadou, Sofia Cordoba, Raul Correa, Juan-Gonzalo and Cuellar-Garcia, Carolina De Paoli, Lorenzo De Paolis, Maria Rosaria Del Poeta, Giovanni Demosthenous, Christos Dimou, Maria Donaldson, David Doubek, Michael Efstathopoulou, Maria and Eichhorst, Barbara El-Ashwah, Shaimaa Enrico, Alicia and Espinet, Blanca Farina, Lucia Ferrari, Angela Foglietta, Myriam Frederiksen, Henrik Furstenau, Moritz Garcia-Marco, Jose A. Garcia-Serra, Rocio Gentile, Massimo Gimeno, Eva and Glenthoj, Andreas da Silva, Maria Gomes Gutwein, Odit and Hakobyan, Yervand K. Herishanu, Yair Angel Hernandez-Rivas, Jose and Herold, Tobias Innocenti, Idanna Itchaki, Gilad Jaksic, Ozren Janssens, Ann Kalashnikova, Olga B. Kalicinska, Elzbieta Karlsson, Linda Katharina Kater, Arnon P. Kersting, Sabina Labrador, Jorge Lad, Deepesh Laurenti, Luca and Levin, Mark-David Lista, Enrico Lopez-Garcia, Alberto and Malerba, Lara Marasca, Roberto Marchetti, Monia Marquet, Juan Mattsson, Mattias Mauro, Francesca R. Milosevic, Ivana and Miras, Fatima Morawska, Marta Motta, Marina Munir, Talha and Murru, Roberta Niemann, Carsten U. Rodrigues, Raquel Nunes and Olivieri, Jacopo Orsucci, Lorella Papaioannou, Maria and Arturo Pavlovsky, Miguel Piskunova, Inga Popov, Viola Maria and Quaglia, Francesca Maria Quaresmini, Giulia Qvist, Kristian and Reda, Gianluigi Rigolin, Gian Matteo Ruchlemer, Rosa and Saghumyan, Gevorg Shrestha, Amit Simkovic, Martin Spacek, Martin Sportoletti, Paolo Stanca, Oana Stavroyianni, Niki and Tadmor, Tamar Te Raa, Doreen Tonino, Sanne H. Trentin, Livio Van der Spek, Ellen van Gelder, Michel van Kampen, Roel Varettoni, Marzia Visentin, Andrea Vitale, Candida and Wasik-Szczepanek, Ewa Wrobel, Tomasz Yanez San Segundo, Lucrecia and Yassin, Mohamed Coscia, Marta Rambaldi, Alessandro and Montserrat, Emili Foa, Robin Cuneo, Antonio Stamatopoulos, Kostas Ghia, Paolo
- Abstract
Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41-0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02-1.04; HR = 1.79, 95% CI:1.04-3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.
- Published
- 2021
12. Long-Term Remissions with MRD-Guided Acalabrutinib, Venetoclax and Obinutuzumab in Relapsed/Refractory CLL: Follow-up Efficacy and Circulating Tumor DNA Analysis of the CLL2-Baag Trial
- Author
-
Furstenau, Moritz, Giza, Adam, Fink, Anna-Maria, Robrecht, Sandra, Weiss, Jonathan, Kleinert, Fanni, Schneider, Christof, Tausch, Eugen, Fischer, Kirsten, Langerbeins, Petra, Al-Sawaf, Othman, Schetelig, Johannes, Dreger, Peter, Böttcher, Sebastian, Kreuzer, Karl-Anton, Ritgen, Matthias, Schilhabel, Anke, Brüggemann, Monika, Stilgenbauer, Stephan, Eichhorst, Barbara F., Hallek, Michael, and Cramer, Paula
- Published
- 2023
- Full Text
- View/download PDF
13. Endpoint Surrogacy in Chronic Lymphocytic Leukemia: A Pooled Analysis of the German CLL Study Group
- Author
-
Simon, Florian, Ligtvoet, Rudy, Robrecht, Sandra, Cramer, Paula, Kutsch, Nadine, Furstenau, Moritz, Goede, Valentin, Von Tresckow, Julia, Langerbeins, Petra, Fink, Anna-Maria, Huber, Henriette, Tausch, Eugen, Schneider, Christof, Wendtner, Clemens-Martin, Ritgen, Matthias, Dreyling, Martin, Müller, Lothar, Jacobasch, Lutz, Heinz, Werner, Vehling-Kaiser, Ursula, Sivcheva, Liliya, Böttcher, Sebastian, Dreger, Peter, Illmer, Thomas, Gregor, Michael, Staber, Philipp Bernhard, Stilgenbauer, Stephan, Niemann, Carsten Utoft, Kater, Arnon P., Fischer, Kirsten, Eichhorst, Barbara F., Hallek, Michael, and Al-Sawaf, Othman
- Published
- 2023
- Full Text
- View/download PDF
14. MRD-Guided Zanubrutinib, Venetoclax and Obinutuzumab after an Optional Debulking with Bendamustine in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Primary Endpoint Analysis of the Phase 2 CLL2-Bzag Study
- Author
-
Furstenau, Moritz, Giza, Adam, Schneider, Christof, Tausch, Eugen, Robrecht, Sandra, Ritgen, Matthias, Bittenbring, Jörg, Hebart, Holger F., Schöttker, Björn, Illert, Anna Lena, Graeven, Ullrich, Stoltefuss, Andrea, Heinrich, Bernhard, Eckert, Robert, Fink, Anna-Maria, Stumpf, Janina, Simon, Florian, Fischer, Kirsten, Al-Sawaf, Othman, Langerbeins, Petra, Kleinert, Fanni, Weiss, Jonathan, Kreuzer, Karl-Anton, Schilhabel, Anke, Brüggemann, Monika, Eichhorst, Barbara F., Stilgenbauer, Stephan, Hallek, Michael, and Cramer, Paula
- Published
- 2023
- Full Text
- View/download PDF
15. Patients with Chronic Lymphocytic Leukemia Carrying t(14;19) Display a Distinctive Transcriptomic Profile and Adverse Outcome, Which Might be Overcome Continuous Therapy with BTK Inhibitors. an Italian Campus CLL and Eric Study
- Author
-
Visentin, Andrea, Gaffo, Enrico, Furstenau, Moritz, Woyach, Jennifer A., Baliakas, Panagiotis, Rogers, Kerry A, Miller, Cecelia, Haferlach, Claudia, Plevova, Karla, Oscier, David Graham, Davis, Zadie, Nguyen Khac, Florence, Roncaglia, Eleonora, Rigolin, Gian Matteo, Athanasiadou, Anastasia, Baran-Marszak, Fanny, Valiente, Alberto, Terol, Maria Jose, Abrisqueta, Pau, Espinet, Blanca, Puiggros, Anna, Martines, Annalisa, Bonaldi, Laura, Mauro, Francesca Romana, Scarfo, Lydia, Chatzikonstantinou, Thomas, Tausch, Eugen, Kreuzer, Karl Anton, Kater, Arnon P., Bosch, Francesc, Doubek, Michael, Panayiotidis, Panayiotis, Kalashnikova, Olga, Frezzato, Federica, Facco, Monica, Ruocco, Valeria, Buratin, Alessia, Orsi, Silvia, Cellini, Alessandro, Angotzi, Francesco, Cavarretta, Chiara Adele, Zatta, Ivan, Serafin, Andrea, Foa, Robin, Eichhorst, Barbara F., Cuneo, Antonio, Stamatopoulos, Kostas, Ghia, Paolo, Bortoluzzi, Stefania, and Trentin, Livio
- Published
- 2023
- Full Text
- View/download PDF
16. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
- Author
-
Chatzikonstantinou, Thomas Kapetanakis, Anargyros Scarfo, Lydia and Karakatsoulis, Georgios Allsup, David Alonso Cabrero, Alejandro Andres, Martin Antic, Darko Baile, Monica and Baliakas, Panagiotis Bron, Dominique Capasso, Antonella and Chatzileontiadou, Sofia Cordoba, Raul Correa, Juan-Gonzalo and Cuellar-Garcia, Carolina De Paoli, Lorenzo De Paolis, Maria Rosaria Del Poeta, Giovanni Demosthenous, Christos Dimou, Maria Donaldson, David Doubek, Michael Efstathopoulou, Maria and Eichhorst, Barbara El-Ashwah, Shaimaa Enrico, Alicia and Espinet, Blanca Farina, Lucia Ferrari, Angela Foglietta, Myriam Frederiksen, Henrik Furstenau, Moritz Garcia-Marco, Jose A. Garcia-Serra, Rocio Gentile, Massimo Gimeno, Eva and Glenthoj, Andreas da Silva, Maria Gomes Gutwein, Odit and Hakobyan, Yervand K. Herishanu, Yair Angel Hernandez-Rivas, Jose and Herold, Tobias Innocenti, Idanna Itchaki, Gilad Jaksic, Ozren Janssens, Ann Kalashnikova, Olga B. Kalicinska, Elzbieta Karlsson, Linda Katharina Kater, Arnon P. Kersting, Sabina Labrador, Jorge Lad, Deepesh Laurenti, Luca and Levin, Mark-David Lista, Enrico Lopez-Garcia, Alberto and Malerba, Lara Marasca, Roberto Marchetti, Monia Marquet, Juan Mattsson, Mattias Mauro, Francesca R. Milosevic, Ivana and Miras, Fatima Morawska, Marta Motta, Marina Munir, Talha and Murru, Roberta Niemann, Carsten U. Rodrigues, Raquel Nunes and Olivieri, Jacopo Orsucci, Lorella Papaioannou, Maria and Arturo Pavlovsky, Miguel Piskunova, Inga Popov, Viola Maria and Quaglia, Francesca Maria Quaresmini, Giulia Qvist, Kristian and Reda, Gianluigi Rigolin, Gian Matteo Ruchlemer, Rosa and Saghumyan, Gevorg Shrestha, Amit Simkovic, Martin Spacek, Martin Sportoletti, Paolo Stanca, Oana Stavroyianni, Niki and Tadmor, Tamar Te Raa, Doreen Tonino, Sanne H. Trentin, Livio Van der Spek, Ellen van Gelder, Michel van Kampen, Roel Varettoni, Marzia Visentin, Andrea Vitale, Candida and Wasik-Szczepanek, Ewa Wrobel, Tomasz Yanez San Segundo, Lucrecia and Yassin, Mohamed Coscia and Chatzikonstantinou, Thomas Kapetanakis, Anargyros Scarfo, Lydia and Karakatsoulis, Georgios Allsup, David Alonso Cabrero, Alejandro Andres, Martin Antic, Darko Baile, Monica and Baliakas, Panagiotis Bron, Dominique Capasso, Antonella and Chatzileontiadou, Sofia Cordoba, Raul Correa, Juan-Gonzalo and Cuellar-Garcia, Carolina De Paoli, Lorenzo De Paolis, Maria Rosaria Del Poeta, Giovanni Demosthenous, Christos Dimou, Maria Donaldson, David Doubek, Michael Efstathopoulou, Maria and Eichhorst, Barbara El-Ashwah, Shaimaa Enrico, Alicia and Espinet, Blanca Farina, Lucia Ferrari, Angela Foglietta, Myriam Frederiksen, Henrik Furstenau, Moritz Garcia-Marco, Jose A. Garcia-Serra, Rocio Gentile, Massimo Gimeno, Eva and Glenthoj, Andreas da Silva, Maria Gomes Gutwein, Odit and Hakobyan, Yervand K. Herishanu, Yair Angel Hernandez-Rivas, Jose and Herold, Tobias Innocenti, Idanna Itchaki, Gilad Jaksic, Ozren Janssens, Ann Kalashnikova, Olga B. Kalicinska, Elzbieta Karlsson, Linda Katharina Kater, Arnon P. Kersting, Sabina Labrador, Jorge Lad, Deepesh Laurenti, Luca and Levin, Mark-David Lista, Enrico Lopez-Garcia, Alberto and Malerba, Lara Marasca, Roberto Marchetti, Monia Marquet, Juan Mattsson, Mattias Mauro, Francesca R. Milosevic, Ivana and Miras, Fatima Morawska, Marta Motta, Marina Munir, Talha and Murru, Roberta Niemann, Carsten U. Rodrigues, Raquel Nunes and Olivieri, Jacopo Orsucci, Lorella Papaioannou, Maria and Arturo Pavlovsky, Miguel Piskunova, Inga Popov, Viola Maria and Quaglia, Francesca Maria Quaresmini, Giulia Qvist, Kristian and Reda, Gianluigi Rigolin, Gian Matteo Ruchlemer, Rosa and Saghumyan, Gevorg Shrestha, Amit Simkovic, Martin Spacek, Martin Sportoletti, Paolo Stanca, Oana Stavroyianni, Niki and Tadmor, Tamar Te Raa, Doreen Tonino, Sanne H. Trentin, Livio Van der Spek, Ellen van Gelder, Michel van Kampen, Roel Varettoni, Marzia Visentin, Andrea Vitale, Candida and Wasik-Szczepanek, Ewa Wrobel, Tomasz Yanez San Segundo, Lucrecia and Yassin, Mohamed Coscia
- Abstract
Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41-0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02-1.04; HR = 1.79, 95% CI:1.04-3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.
- Published
- 2021
17. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
- Author
-
Chatzikonstantinou, Thomas, Kapetanakis, Anargyros, Scarfo, Lydia, Karakatsoulis, Georgios, Allsup, David, Alonso Cabrero, Alejandro, Andres, Martin, Antic, Darko, Baile, Monica, Baliakas, Panagiotis, Bron, Dominique, Capasso, Antonella, Chatzileontiadou, Sofia, Cordoba, Raul, Correa, Juan-Gonzalo, Cuellar-Garcia, Carolina, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Demosthenous, Christos, Dimou, Maria, Donaldson, David, Doubek, Michael, Efstathopoulou, Maria, Eichhorst, Barbara, El-Ashwah, Shaimaa, Enrico, Alicia, Espinet, Blanca, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Frederiksen, Henrik, Furstenau, Moritz, Garcia-Marco, Jose A., Garcia-Serra, Rocio, Gentile, Massimo, Gimeno, Eva, Glenthoj, Andreas, da Silva, Maria Gomes, Gutwein, Odit, Hakobyan, Yervand K., Herishanu, Yair, Angel Hernandez-Rivas, Jose, Herold, Tobias, Innocenti, Idanna, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Olga B., Kalicinska, Elzbieta, Karlsson, Linda Katharina, Kater, Arnon P., Kersting, Sabina, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Lopez-Garcia, Alberto, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Marquet, Juan, Mattsson, Mattias, Mauro, Francesca R., Milosevic, Ivana, Miras, Fatima, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Niemann, Carsten U., Rodrigues, Raquel Nunes, Olivieri, Jacopo, Orsucci, Lorella, Papaioannou, Maria, Arturo Pavlovsky, Miguel, Piskunova, Inga, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, Qvist, Kristian, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Saghumyan, Gevorg, Shrestha, Amit, Simkovic, Martin, Spacek, Martin, Sportoletti, Paolo, Stanca, Oana, Stavroyianni, Niki, Tadmor, Tamar, Te Raa, Doreen, Tonino, Sanne H., Trentin, Livio, Van der Spek, Ellen, van Gelder, Michel, van Kampen, Roel, Varettoni, Marzia, Visentin, Andrea, Vitale, Candida, Wasik-Szczepanek, Ewa, Wrobel, Tomasz, Yanez San Segundo, Lucrecia, Yassin, Mohamed, Coscia, Marta, Rambaldi, Alessandro, Montserrat, Emili, Foa, Robin, Cuneo, Antonio, Stamatopoulos, Kostas, Ghia, Paolo, Chatzikonstantinou, Thomas, Kapetanakis, Anargyros, Scarfo, Lydia, Karakatsoulis, Georgios, Allsup, David, Alonso Cabrero, Alejandro, Andres, Martin, Antic, Darko, Baile, Monica, Baliakas, Panagiotis, Bron, Dominique, Capasso, Antonella, Chatzileontiadou, Sofia, Cordoba, Raul, Correa, Juan-Gonzalo, Cuellar-Garcia, Carolina, De Paoli, Lorenzo, De Paolis, Maria Rosaria, Del Poeta, Giovanni, Demosthenous, Christos, Dimou, Maria, Donaldson, David, Doubek, Michael, Efstathopoulou, Maria, Eichhorst, Barbara, El-Ashwah, Shaimaa, Enrico, Alicia, Espinet, Blanca, Farina, Lucia, Ferrari, Angela, Foglietta, Myriam, Frederiksen, Henrik, Furstenau, Moritz, Garcia-Marco, Jose A., Garcia-Serra, Rocio, Gentile, Massimo, Gimeno, Eva, Glenthoj, Andreas, da Silva, Maria Gomes, Gutwein, Odit, Hakobyan, Yervand K., Herishanu, Yair, Angel Hernandez-Rivas, Jose, Herold, Tobias, Innocenti, Idanna, Itchaki, Gilad, Jaksic, Ozren, Janssens, Ann, Kalashnikova, Olga B., Kalicinska, Elzbieta, Karlsson, Linda Katharina, Kater, Arnon P., Kersting, Sabina, Labrador, Jorge, Lad, Deepesh, Laurenti, Luca, Levin, Mark-David, Lista, Enrico, Lopez-Garcia, Alberto, Malerba, Lara, Marasca, Roberto, Marchetti, Monia, Marquet, Juan, Mattsson, Mattias, Mauro, Francesca R., Milosevic, Ivana, Miras, Fatima, Morawska, Marta, Motta, Marina, Munir, Talha, Murru, Roberta, Niemann, Carsten U., Rodrigues, Raquel Nunes, Olivieri, Jacopo, Orsucci, Lorella, Papaioannou, Maria, Arturo Pavlovsky, Miguel, Piskunova, Inga, Popov, Viola Maria, Quaglia, Francesca Maria, Quaresmini, Giulia, Qvist, Kristian, Reda, Gianluigi, Rigolin, Gian Matteo, Ruchlemer, Rosa, Saghumyan, Gevorg, Shrestha, Amit, Simkovic, Martin, Spacek, Martin, Sportoletti, Paolo, Stanca, Oana, Stavroyianni, Niki, Tadmor, Tamar, Te Raa, Doreen, Tonino, Sanne H., Trentin, Livio, Van der Spek, Ellen, van Gelder, Michel, van Kampen, Roel, Varettoni, Marzia, Visentin, Andrea, Vitale, Candida, Wasik-Szczepanek, Ewa, Wrobel, Tomasz, Yanez San Segundo, Lucrecia, Yassin, Mohamed, Coscia, Marta, Rambaldi, Alessandro, Montserrat, Emili, Foa, Robin, Cuneo, Antonio, Stamatopoulos, Kostas, and Ghia, Paolo
- Abstract
Patients with chronic lymphocytic leukemia (CLL) may be more susceptible to Coronavirus disease 2019 (COVID-19) due to age, disease, and treatment-related immunosuppression. We aimed to assess risk factors of outcome and elucidate the impact of CLL-directed treatments on the course of COVID-19. We conducted a retrospective, international study, collectively including 941 patients with CLL and confirmed COVID-19. Data from the beginning of the pandemic until March 16, 2021, were collected from 91 centers. The risk factors of case fatality rate (CFR), disease severity, and overall survival (OS) were investigated. OS analysis was restricted to patients with severe COVID-19 (definition: hospitalization with need of oxygen or admission into an intensive care unit). CFR in patients with severe COVID-19 was 38.4%. OS was inferior for patients in all treatment categories compared to untreated (p < 0.001). Untreated patients had a lower risk of death (HR = 0.54, 95% CI:0.41-0.72). The risk of death was higher for older patients and those suffering from cardiac failure (HR = 1.03, 95% CI:1.02-1.04; HR = 1.79, 95% CI:1.04-3.07, respectively). Age, CLL-directed treatment, and cardiac failure were significant risk factors of OS. Untreated patients had a better chance of survival than those on treatment or recently treated.
- Published
- 2021
18. Bendamustine followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia: primary endpoint analysis of a multicenter, open-label, phase II trial (CLL2-BIO)
- Author
-
Cramer, Paula, von Tresckow, Julia, Robrecht, Sandra, Bahlo, Jasmin, Furstenau, Moritz, Langerbeins, Petra, Pflug, Natali, Al-Sawaf, Othman, Heinz, Werner J., Vehling-Kaiser, Ursula, Durig, Jan, Tausch, Eugen, Hensel, Manfred, Sasse, Stephanie, Fink, Anna-Maria, Fischer, Kirsten, Kreuzer, Karl-Anton, Boettcher, Sebastian, Ritgen, Matthias, Kneba, Michael, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Eichhorst, Barbara, Hallek, Michael, Cramer, Paula, von Tresckow, Julia, Robrecht, Sandra, Bahlo, Jasmin, Furstenau, Moritz, Langerbeins, Petra, Pflug, Natali, Al-Sawaf, Othman, Heinz, Werner J., Vehling-Kaiser, Ursula, Durig, Jan, Tausch, Eugen, Hensel, Manfred, Sasse, Stephanie, Fink, Anna-Maria, Fischer, Kirsten, Kreuzer, Karl-Anton, Boettcher, Sebastian, Ritgen, Matthias, Kneba, Michael, Wendtner, Clemens-Martin, Stilgenbauer, Stephan, Eichhorst, Barbara, and Hallek, Michael
- Abstract
The introduction of targeted agents has revolutionized the treatment of chronic lymphocytic leukemia but only few patients achieve a complete remission and minimal residual disease negativity with ibrutinib monotherapy. This multicenter, investigator-initiated, phase II study is evaluating sequential treatment with two cycles of bendamustine debulking for patients with a higher tumor load, followed by ofatumumab and ibrutinib induction and maintenance treatment. An all-comer population, irrespective of prior treatment, physical fitness and genetic factors, was included. The primary endpoint was the investigator-assessed overall response rate at the end of induction treatment. Of 66 patients enrolled, one patient with early treatment discontinuation was excluded from the efficacy analysis as predefined by the protocol. Thirty-nine patients (60%) were treatment-naive and 26 patients (40%) had relapsed/refractory chronic lymphocytic leukemia, 21 patients (32%) had a del(17p) and/or TP53 mutation and 45 patients (69%) had unmutated IGHV status. At the end of the induction, 60 of 65 patients (92%) responded and nine (14%) achieved minimal residual disease negativity (<10(-4)) in peripheral blood. No unexpected or cumulative toxicities occurred. The most common grade 3 or 4 adverse events, according to the Common Toxicity Criteria, were neutropenia, anemia, infusion-related reactions, and diarrhea. This sequential treatment of bendamustine debulking, followed by ofatumumab and ibrutinib was well tolerated without unexpected safety signals and showed a good efficacy with an overall response rate of 92%. Ongoing maintenance treatment aims at deeper responses with minimal residual disease negativity. However, ibrutinib should still be used as a single agent outside clinical trials.
- Published
- 2021
19. Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations
- Author
-
Cramer, Paula, Tausch, Eugen, von Tresckow, Julia, Giza, Adam, Robrecht, Sandra, Schneider, Christof, Furstenau, Moritz, Langerbeins, Petra, Al-Sawaf, Othman, Pelzer, Benedikt W., Fink, Anna Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Eichhorst, Barbara, Kneba, Michael, Stilgenbauer, Stephan, Hallek, Michael, Cramer, Paula, Tausch, Eugen, von Tresckow, Julia, Giza, Adam, Robrecht, Sandra, Schneider, Christof, Furstenau, Moritz, Langerbeins, Petra, Al-Sawaf, Othman, Pelzer, Benedikt W., Fink, Anna Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Eichhorst, Barbara, Kneba, Michael, Stilgenbauer, Stephan, and Hallek, Michael
- Abstract
Fifty-one of 189 evaluable patients from 3 prospective phase 2 trials evaluating a sequential targeted treatment had high-risk chronic lymphocytic leukemia (CLL) with a 17p deletion, TP53 mutation, or both. Twenty-seven patients started treatment with bendamustine debulking before induction and maintenance treatment, which was ibrutinib/ofatumumab (IO) in 21 patients, ibrutinib/obinutuzumab (IG) in 13, and venetoclax/obinutuzumab (AG) in 17. The primary end point was overall response rate after 8 months of induction treatment, which was 81%, 100%, and 94% for IO, IG, and AG, respectively. Minimal residual disease (MRD) was undetectable (uMRD) in peripheral blood (<10(-4) by flow cytometry) in 0%, 23%, and 82% of patients, respectively. Median progression-free survival (PFS) was 45 months. Seventeen patients discontinued maintenance treatment due to uMRD: 9 progressed, 2 died without progression (median PFS, 28 months after discontinuation of treatment), and 6 remained in remission after a median observation time of 46 months (range, 6-47 months) after treatment discontinuation. Thus, MRD-guided fixed-duration therapies combining obinutuzumab with venetoclax or ibrutinib can induce deep and durable remissions in CLL patients with high-risk genetic lesions, which can persist after treatment discontinuation (due to a predefined fixed-duration or MRD-guided early termination). The median PFS was 45 months.
- Published
- 2021
20. High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53Aberrations Treated with Venetoclax-Based Time-Limited Combinations
- Author
-
Furstenau, Moritz, Thus, Yvonne, Robrecht, Sandra, Mellink, Clemens, Van Der Kevie-Kersemaekers, Anne-Marie, Dubois, Julie M.N., Von Tresckow, Julia, Patz, Michaela, Gregor, Michael, Thornton, Patrick, Staber, Philipp B., Tadmor, Tamar, Levin, Mark-David, Da Cunha-Bang, Caspar, Schneider, Christof, Poulsen, Christian Bjørn, Illmer, Thomas, Schöttker, Björn, Janssens, Ann, Christiansen, Ilse, Baumann, Michael, Noesslinger, Thomas, Regelink, Josien, Dompeling, Ellen C, Lindström, Vesa, Juliusson, Gunnar, Widmer, Anouk, Goede, Jeroen Simon, Goldschmidt, Neta, Simon, Florian, De Silva, Nisha, Fink, Anna-Maria, Fischer, Kirsten, Wendtner, Clemens-Martin, Ritgen, Matthias, Brüggemann, Monika, Tausch, Eugen, Stilgenbauer, Stephan, Eldering, Eric, Niemann, Carsten Utoft, Hallek, Michael, Eichhorst, Barbara, Kreuzer, Karl-Anton, and Kater, Arnon P.
- Published
- 2022
- Full Text
- View/download PDF
21. How to approach CLL in clinical practice
- Author
-
Hallek, Michael, Furstenau, Moritz, Hallek, Michael, and Furstenau, Moritz
- Published
- 2019
22. Residual Abdominal Lymphadenopathy after Intensive Frontline Chemoimmunotherapy Is Associated with Inferior Outcome Regardless of MRD Status in Advanced Chronic Lymphocytic Leukemia (CLL)
- Author
-
Furstenau, Moritz, Bahlo, Jasmin, Fink, Anna-Maria, Lange, Elisabeth, Dreger, Peter, Dreyling, Martin, Hess, Georg, Ritgen, Matthias, Kneba, Michael, Doehner, Hartmut, Stilgenbauer, Stephan, Wendtner, Clemens-Martin, Goede, Valentin, Fischer, Kirsten, Boettcher, Sebastian, Hallek, Michael, Eichhorst, Barbara, Furstenau, Moritz, Bahlo, Jasmin, Fink, Anna-Maria, Lange, Elisabeth, Dreger, Peter, Dreyling, Martin, Hess, Georg, Ritgen, Matthias, Kneba, Michael, Doehner, Hartmut, Stilgenbauer, Stephan, Wendtner, Clemens-Martin, Goede, Valentin, Fischer, Kirsten, Boettcher, Sebastian, Hallek, Michael, and Eichhorst, Barbara
- Published
- 2018
23. Zur Geschichte der Musik und des Theaters am Hofe zu Dresden
- Author
-
Marion, M., primary, Marion, C., additional, Fürstenau, Moritz, additional, Reich, Wolfgang, additional, and Furstenau, Moritz, additional
- Published
- 1976
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.